Rekombinanter TNFSF9 Antikörper

Produktnummer ABIN7072493

Produktdetails anti-TNFSF9 Antikörper

Target: TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))

Antikörpertyp: Recombinant Antibody

Reaktivität: Maus

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser TNFSF9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Flow Cytometry (FACS), Blocking Peptide (BP)

Verwendungszweck: Anti-4-1BBL [AT113-2], Rabbit IgG, kappa

Spezifität: This antibody is specific for 4-1BB ligand (also known as CD137 ligand), which is a member of the TNF superfamily and is a type II membrane protein. 4-1BB ligand is a co-stimulatory molecule that is expressed on antigen presenting cells (DCs, monocytes/macrophages, B cells) and is upregulated upon activation of these cells. Both of the 4-1BB ligand and its receptor, TNFRSF9/4-1BB, are involved in the antigen presentation process and in the generation of cytotoxic T cells. In direct ELISAs, no cross-reactivity with recombinant human RELT is observed.

Produktmerkmale:

Original Species of Ab: Rat

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Immunogen: This antibody was raised by immunising LOU rats with soluble recombinant 4-1BBL:Fc fusion protein.

Klon: AT113-2

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: This antibody has been used in various FACS analyses, for instance, to show that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for dendritic cell-driven accumulation of antitumor cytotoxic T lymphocytes following anti-CD40 mAb treatment (French et al, 2007), to examine the underlying mechanisms of the differential T cell costimulation dependence in viral infections (Welten et al, 2015), and to explore the therapeutic benefit of using combinations of syngeneic tumor vaccines that express immune modulators (Manrique-Rincón et al, 2017). This antibody has been used as a blocking antibody, together with anti-CD70, anti-CD30L and anti-OX40L antibodies, to evaluate OX40 ligand and CD70 in the promotion of CD4+ T cell responses (Kurche et al, 2010). Furthermore, this anti-4-1BBL antibody has been used alongside the anti-CD70, anti-CD27, anti-CD40 antibodies in a BCL1-bearing mouse model to evaluate the theurapeutic potency of various combined immmunotherapies against lymphoma (French et al, 2007).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu TNFSF9

Target: TNFSF9 (Tumor Necrosis Factor (Ligand) Superfamily, Member 9 (TNFSF9))

Andere Bezeichnung: 4-1BBL (TNFSF9 Produkte)

Hintergrund: CD137L, TNFSF9, 4-1BB ligand, 41BBL, CDw137L, homolog of mouse 4-1BB-L, receptor 4-1BB ligand, tumor necrosis factor (ligand) superfamily member 9, tumor necrosis factor (ligand) superfamily, member 9, tumor necrosis factor ligand 5A, Tumor necrosis factor ligand superfamily member 9.

UniProt: P41274

Pathways: Activated T Cell Proliferation, Cancer Immune Checkpoints